Two cases of gynaecomastia with cetirizine, a second-generation antihistamine

Therapie

Volumn 59, Issue 1, 2004, Pages 163-164

  Louis, Marie Pierre ^a   Héran, Isabelle ^a   Peyrière, Hélène ^a   Blayac, Jean Pierre ^a   Hillaire Buys, Dominique ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Antihistamine; Cetirizine; Dopamine; Gynaecomastia; Hyperprolactinaemia

Indexed keywords

AMYLASE; ANTIHISTAMINIC AGENT; CETIRIZINE; DOPAMINE; LORATADINE; MEQUITAZINE; PROLACTIN;

ALLERGIC RHINITIS; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMALE; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; LETTER; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 2942659107     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2004031     Document Type: Letter

References (6)

1. Lazala C, Saenger P. Pubertal gynecomastia. J Pediatr Metab 2002; 15: 553-60
2. Braunstein GD. Current concepts: gynecomastia. N Engl J Med 1993; 328: 490-5
3. Hugues FC, Gourlot C, Le Jeune C. Drug-induced gynecomastia. Ann Med Intern 2000; 151: 10-7
4. Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy 1993; 13: 37-45
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45
6. Maguire GA. Prolactine elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63 Suppl. 4: 56-62